OKYO Pharma Ltd Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by OKYO Pharma Ltd on July 22, 2026. The filing serves to disclose a significant change in beneficial ownership by the Company's Chairman, Mr. Gabriele Cerrone, acting through Panetta Partners Ltd.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a share purchase transaction rather than financial performance.
Material Changes
- Share Purchase: Mr. Gabriele Cerrone purchased 22,500 ordinary shares at a price of $1.45 per share.
- Updated Holdings: Following the purchase, his total holding stands at 10,873,916 ordinary shares.
- Ownership Percentage: The Chairman's beneficial interest now represents 20.55% of the Company's issued share capital.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is a procedural disclosure of the share transaction and incorporates the news announcement as Exhibit 99.1.
Investor Verification Checklist
- Verify the total issued share capital to confirm the 20.55% ownership calculation.
- Review the attached Exhibit 99.1 for the full text of the news announcement.
- Confirm the beneficial interest structure of Panetta Partners Ltd.
- Check subsequent filings for any further changes in the Chairman's holdings.